SPD 473
Alternative Names: BTS 74398Latest Information Update: 16 Jan 2019
Price :
£46 *
At a glance
- Originator Abbott GmbH & Co. KG
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Major depressive disorder; Parkinson's disease
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 30 Jul 2004 Discontinued - Phase-II for Attention-deficit hyperactivity disorder in Europe (unspecified route)
- 02 Oct 2002 Discontinued - Phase-II for Depression in Europe (unspecified route)